MUHAMMAD SHAMSI: Open Payments
NPI 1609843721 · PLYMOUTH MEETING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,191 in 66 payments from 17 companies in 2025. Trend: 2023 $7,871 · 2024 $3,126 · 2025 $1,191
Food & beverage: $1,191
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $205 |
| Otsuka America Pharmaceutical, Inc. | 7 | $170 |
| E.R. Squibb & Sons, L.L.C. | 4 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $99 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Alkermes, Inc. | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Tris Pharma Inc | 3 | $60 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Almatica Pharma LLC | 2 | $47 |
Products named: VRAYLAR, REXULTI, COBENFY, CAPLYTA, FANAPT, ARISTADA, Dyanavel XR, INGREZZA.
Industry payments across PA — which companies pay providers there.
